30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 1 FDA Drug Development Overview

This podcast episode provides a comprehensive overview of the FDA drug development process for cannabinoid and psychedelic therapeutics. The hosts discuss the journey from pre-clinical research through post-marketing surveillance, explaining key stages including:- Pre-clinical research and molecular interactions with brain receptors- The IND (Investigational New Drug) application process- The three phases of clinical trials and their purposes- Special challenges related to Schedule I substances and regulatory hurdlesThe conversation also explores broader implications for mental health treatment and addiction, emphasizing how these emerging therapies could reshape our understanding of healing and consciousness.